FindTrial
Sign In

Prospective study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in diagnosis, treatment and prognosis for Neuroendocrine Neoplasms

Prospective study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in diagnosis, treatment and prognosis for Neuroendocrine Neoplasms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100506
Enrollment
Unknown
Registered
2025-04-10
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine Neoplasms

Interventions

Gold Standard:The pathological diagnosis from biopsy or surgery is the gold standard
Index test:18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging

Sponsors

The First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) patients suspected of neuroendocrine tumor by clinical or imaging in our hospital; (2) patients with previously diagnosed neuroendocrine tumors and suspected recurrence or metastasis.

Exclusion criteria

Exclusion criteria: (1)Not suitable for preoperative puncture unable to undergo surgical treatment; (2)Simultaneously diagnosed with other active malignant tumors or a history of other malignant tumors within the last 5 years; (4)Severe uncontrolled diseases or active infections; (5)Unable to provide informed consent for the study.

Design outcomes

Primary

MeasureTime frame
SUVmax;—

Secondary

MeasureTime frame
SUVmean;MTV;—

Countries

China

Contacts

Public ContactDonghe Chen

The First Affiliated Hospital, Zhejiang University School of Medicine

chendonghe@zju.edu.cn+86 137 7745 2235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026